Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Akihito Kawazoe,Noboru Yamamoto,Naotoshi Sugimoto,Hisato Kawakami,Takashi Oshima,Kensei Yamaguchi,Kaori Hino,Motohiro Hirao,Yukinori Kurokawa,Takeshi Kawakami,Masahiro Tsuda,Hiroki Hara, Shota Kaname,Daiko Matsuoka,Yohei Otake, Keisuke Yasuda,Takao Takase, Shuya Takashima,Taro Semba,Kei Muro

crossref（2024）

引用 0|浏览2

暂无评分

摘要

Supplementary Table S3. Tumor responses as assessed by investigator using RECIST v1.1 by prior gastrectomy or liver metastasis at baseline, and by prior ICI treatment

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要